The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York RFK Jr. & claimed regenerative peptides like BPC 157 The Niche BPC 157 Ulcerative Colitis LIVV Natural FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling